At Rebiotix Inc., a Ferring Company, we are looking for talented, enthusiastic, and dedicated people seeking to make a difference in people’s lives by working on therapies for challenging gastrointestinal diseases. We offer creative and agile people the opportunity to work on an entirely new category of biologic drugs based on expanding knowledge of the human microbiome.
If you are interested in working for an innovative company that appreciates your contributions and individuality, while fostering teamwork, then Rebiotix may be the place for you.
We seek highly motivated and professional individuals who have a passion for what they do and who desire to make a difference.
It is the policies of Rebiotix and Ferring to provide equal employment opportunity (EEO) to all persons regardless of age, color, national origin, citizenship status, physical or mental disability, race, religion, creed, gender, sex, sexual orientation, gender identity and/or expression, genetic information, marital status, status with regard to public assistance, veteran status, or any other characteristic protected by federal, state or local law.
Current Openings
Click on any of the links below to learn more about a specific position and apply.
- Associate Director of Clinical Operations (Minneapolis)
- Associate Director of Regulatory Affairs (Minneapolis)
- Donor Assistant (Minneapolis)
- Equipment Program Coordinator (Minneapolis)
- Facility Engineering Manager (Minneapolis)
- Facility Technician (Minneapolis)
- Manufacturing Engineering Manager (Minneapolis)
- Manufacturing Technician I (Minneapolis)
- Manufacturing Technician I (Minneapolis)
- Quality Operations Manager (Minneapolis)
- Quality Operations Supervisor (Minneapolis)
- Quality Operations Technician (Minneapolis)
- Senior Associate, Project Management (Minneapolis)
- Senior Clinical Research Associate (Minneapolis)
- Senior Facility Technician (Minneapolis)
- Scientist, Microbiome Analysis (Minneapolis)
- Shipping, Receiving, Inventory Specialist (Minneapolis)
Updated July 21, 2021.